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Angioimmunoblastic T-cell lymphoma (AITL) is one of four major subtypes of nodal
peripheral T cell lymphoma, characterized by its cell of origin, the follicular helper T-cell
(TFH). Patients typically present with prominent constitutional (B) symptoms, generalized
lymphadenopathy, hepatosplenomegaly, cytopenias, and rash. Here we present a case
of a 62-year-old male with progressive cervical adenopathy, fevers and weight loss
presenting with extreme polyclonal plasmacytosis and high plasma EBV viral load. While
the initial presentation appeared to mimic plasma cell leukemia or severe infection,
lymph node biopsy and bone marrow biopsy confirmed a diagnosis of AITL. This case
highlights the heterogeneity of the clinical presentation of AITL to enable physicians to
more promptly recognize, diagnose and initiate treatment.
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INTRODUCTION
Angioimmunoblastic T cell lymphoma (AITL) is recognized in the 2016 World Health
Organization (WHO) Classification as one of the four major subtypes of nodal peripheral
T cell lymphoma (PTCL), accounting for 15–25% of all PTCL, depending on geographical
region, and approximately 1–2% of all non-Hodgkin lymphomas (NHL) (1). AITL is a clinically
distinct lymphoid neoplasm, with a well-characterized cell of origin, the follicular helper
T-cell (TFH), and with discrete immunophenotypical and genetic features. Most patients with
AITL present with very prominent constitutional (B) symptoms, generalized lymphadenopathy,
hepatosplenomegaly, multilineage cytopenias (in particular thrombocytopenia), and rash (2).
These symptoms may precede the diagnosis by several months, rarely by years. Laboratory signs of
B-cell activation and autoimmunity are a hallmark of AITL, including hypergammaglobulinemia,
autoimmune hemolytic anemia (AIHA), immune mediated thrombocytopenia (ITP), and presence
of autoantibodies (rheumatoid factor, anti-phospholipid, anti-DNA, and anti-smooth muscle
antibodies). The majority of AITL patients have detectable Epstein Bar Virus (EBV)-encoded RNA
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(EBER)-positive cells by in situ hybridization (ISH) (3). in
the diagnostic lymph node biopsy and about 50% have
measurable plasma EBVDNA (pEBVd) (4), even before initiation
of chemotherapy which may contribute to polyclonal B-cell
activation and lead to the development of EBV-positive B-
cell lymphomas in a subset of patients. While in most
cases the hypergammaglobulinemia is polyclonal, monoclonal
immunoglobulins (Ig) can be detected in the serum of some
patients, mimicking multiple myeloma (5).
There are several reported cases of marked peripheral blood
and/or bone marrow plasmacytosis in AITL, mimicking
plasma cell leukemia, especially when associated with
elevated Ig levels. The polyclonal nature of the plasmacytosis,
however, ultimately suggests a reactive etiology, such a viral
infection (EBV, parvovirus B19, hepatitis), autoimmune
disease (rheumatoid arthritis, systemic lupus erythematosus,
Sjögren’s syndrome), or serum sickness (6, 7). EBV has an
established association with numerous B-cell and T cell
lymphoproliferative neoplasms, including AITL (8, 9). Here
we report the case of a patient with AITL who presented with
marked peripheral blood polyclonal plasmacytosis, polyclonal
hypergammaglobulinemia, and high levels of pEBVd, suggestive
of EBV reactivation. The case highlights the heterogeneity of
the clinical manifestations of AITL, to enable physicians to
more readily recognize the disease at presentation and initiate
treatment promptly.
CASE PRESENTATION
A 62-year-old male, with a history of non-ischemic
cardiomyopathy presented with new onset atrial flutter. He
reported shortness of breath, diaphoresis and lightheadedness
for ∼ 1 week as well as progressive cervical adenopathy,
fevers, and unintentional weight loss. Laboratory evaluation
demonstrated white blood cell (WBC) count of 17.3 × 109/L
with 37% (6.4 × 109/L) plasma cells, hemoglobin of 11.6
g/dL, and platelet count of 53 × 109/L. Contrast-enhanced
computed tomography (CT) scans of the chest, abdomen,
and pelvis revealed non-bulky cervical, axillary, mediastinal,
retroperitoneal and inguinal lymphadenopathy, ranging in
size between 1.4 cm and 2.5 cm, as well as splenomegaly of
15.5 cm, without discrete lesions. Shortly after admission, the
patient developed acute renal failure and serum electrolyte
abnormalities consistent with tumor lysis syndrome (TLS)
(creatinine of 4.2 mg/dL, potassium of 5.4 mmol/L, phosphate
of 5.3 mg/dL, urate of 11.9 mg/dL, lactate dehydrogenase of
368 IU/L). Peripheral blood flow cytometry revealed that 46%
of the leukocytes were represented by polyclonal plasma cells
(CD19+, CD20−, CD22−, CD45+(moderate), CD38+(bright),
CD56−, CD117−, CD138+, HLA-DR+(heterogeneous), surface
κ or λ−, cytoplasmic κ +(subset), cytoplasmic λ+(subset)).
Serum protein electrophoresis (SPEP) and immunofixation
electrophoresis (IFE) showed abnormally high gamma globulin
levels (IgA 1200mg/dL and IgG 4200mg/dL) without a
monoclonal paraprotein. Serum kappa and lambda light chain
levels were modestly elevated (92.6 mg/dL and 73 mg/dL,
respectively) but the ratio was normal (1.27).
There was initial concern for an infectious etiology for the
patient’s presentation given the signs of systemic inflammatory
response syndrome (tachycardia, leukocytosis, fever) and
circulating polyclonal plasma cells. Blood cultures and viral
studies were performed and were notable for a detectable plasma
EBV viral load, which was quantified by qRT-PCR as 71,000
copies/mL of pEBVd, and approximately 24 h later increased to
1.05 × 106 copies/mL. Human immunodeficiency virus (HIV)
and hepatitis C serologies were negative, hepatitis B serology was
consistent with prior immunization, and plasma cytomegalovirus
DNA (pCMVd)was negative. Serum antinuclear antibody (ANA)
titer for initial workup of autoimmune disease was also negative.
After bone marrow and lymph node biopsies were obtained,
dexamethasone 40mg daily was initiated, as concerns for an
EBV associated lymphoproliferative disorder (EBV-LPD) were
high. In addition, the patient was started on antiviral therapy
with ganciclovir 2.5 mg/kg IV every 12 h for possible active
EBV infection. The drug was stopped after 5 days as the treating
physicians concluded that the risk of drug toxicity outweighed
the benefit, and the data to support its use in this setting were
insufficient. Despite these measures and aggressive supportive
care, within 1 week of admission, his clinical course progressed
to multiorgan failure requiring mechanical ventilation and
ultimately cardiac arrest requiring extracorporeal membrane
oxygenation (ECMO).
Bone marrow exam revealed hypercellularity (90%) with 30–
40% plasma cells (which was deemed to be reactive because of
polyclonal kappa/lambda expression), large lymphoid aggregates
with predominance of T cells, and scattered EBV+ B cells.
Molecular studies for T-cell receptor (TCR) gamma gene and
immunoglobulin heavy chain (IGH) gene rearrangements were
performed on the blood sample. Amonoclonal TCR gamma gene
rearrangement was detected; clonal IGH gene rearrangement was
not detected. The left inguinal node showed completely effaced
normal lymph node architecture with a diffuse infiltration of
atypical small to medium sized lymphocytes in a background of
vascular proliferation, plasma cells, and scattered immunoblasts.
By immunohistochemistry and flow cytometry, there was a
diffusely increased T cells infiltrate admixed with scattered B
immunoblasts. The T cells expressed CD2, CD3, CD5, CD7,
PD-1, and were negative for CD5, CD10, BCL-6, and all B-
cell antigens analyzed. CD4 to CD8 ratio was within normal
range. Scattered large immunoblasts were positive for CD20
and EBV (by EBER in situ hybridization). CD21 revealed
several expanded clusters of follicular dendritic cells. In situ
hybridization for immunoglobulin kappa and lambda light
chains revealed numerous polyclonal plasma cells. Molecular
studies for TCR gamma gene and IGH gene rearrangements
were repeated on the lymph node. Identical clonal TCR gamma
gene rearrangement was detected in the lymph node. Similarly,
clonal IGH gene rearrangement was not detected. Representative
images are shown in Figure 1.
In aggregate, these findings were thought to bemost consistent
with a diagnosis of AITL. Pathologically, the complete effacement
of nodal architecture, diffuse involvement of bone marrow,
and the presence of clonal T-cell gene rearrangement rule
out conditions of reactive EBV infection such as infectious
mononucleosis and chronic active EBV infection. Unfortunately,
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FIGURE 1 | Pathologic features of blood, bone marrow, and lymph node. (A) The blood smear showed a marked increase of reactive circulating plasma cells. (B)
Bone marrow biopsy showed diffuse infiltration of atypical lymphocytes admixed with numerous reactive plasma cells. (C) The left inguinal lymph node revealed diffuse
infiltration of small to medium-sized atypical lymphocytes and scattered large immunoblasts, with exuberant vascular proliferation and numerous reactive plasma cells.
(D–F). The atypical lymphocytes expressed CD3 (D). Scattered immunoblasts expressed CD20 (E) and EBER by in situ hybridization (F) (Magnification: A. x100,
B–F. x40).
the patient failed to improve with dexamethasone and the family
decided to withdraw care. A request for autopsy was declined.
DISCUSSION
In this report we present a case of AITL with profound
polyclonal peripheral plasmacytosis and rapidly rising pEBVd,
reaching extremely high levels (>1 million copies/mL). This
presentation offered a significant challenge as plasma cell
leukemia and a severe systemic infection were the initial
diagnostic considerations.
AITL is an aggressive subtype of nodal peripheral T cell
lymphomas. It is derived from follicular helper T-cells (TFH)
that normally reside at the border between the mantle zone and
the germinal center of the normal physiologic lymph node (10).
TFH are a distinct subset of T helper cells necessary for the
formation of germinal centers (GC) and B-cell differentiation.
They are formed through naïve CD4+ T-cell’s interaction with
dendritic cells, leading to the activation of the inducible T-cell
costimulator (ICOS) and phosphatidylinositol 3-kinase (PI3K)
pathways in the CD4+ T-cells. This induces the expression of B-
cell lymphoma 6 protein (BCL6), along with other transcription
factors which guides the differentiation of the naïve CD4+T-cells
into TFH (10, 11) TFH then help in directing the differentiation
of B-cell centroblasts to centrocytes, which ultimately form
plasma cells or memory B cells (10). TFH begin to express
high levels of C-X-C chemokine receptor type 5 (CXCR5), PD-
1, BCL6, myelin-associated glycoprotein (MAG), and serum
amyloid P component (SAP), the expression of which can
be detected by immunohistochemistry (IHC). The genetic
alterations thought to be driving the development of AITL
include ten eleven translocation methylcytosine dioxygenase 2
(TET2), DNA (cytosine-5)-methyltransferase 3A (DNMT3A),
isocitrate dehydrogenase (NADP(+)) 2 (IDH2), ras homolog
gene family member A (RHOA), and components of the TCR
pathways, all of which are potentials targets for therapy (11).
Histologic examination of involved lymph nodes in AITL
shows small-medium sized tumor cells in small clusters
with clear cytoplasm, that can be identified as TFH by
immunohistochemistry, based on the expression of PD-1 and
CXCL13 (CXCR5 ligand) and pan T-cell markers, such as CD3
and CD4 (12). The associated FDC are typically identified by
expression of CD21, CD23, and CD35. These two cell types are
present among a population of other small reactive lymphocytes,
histiocytes, and plasma cells, with high endothelial venules (13).
The B-cells are often EBV+ (EBER+), while the associated T
cells and plasma cells are typically not (14). This morphologic
appearance can initially be mistaken for a hyperplastic reactive
lymph node with EBV reactivation.
In a retrospective subset analysis of 157 patients with AITL
enrolled on the GELA (Groupe d’Etude des Lymphomes de
l’Adulte) LNH87 and LNH93 randomized clinical trials, bone
marrow involvement was seen in 60% of patients (14). The
most commonly seen features were paratrabecular and interstitial
infiltration of atypical lymphocytes, histiocytes and eosinophils,
with infiltration of small to large B cells. Vascular proliferation
and reticulin fibrosis have also been reported. Secondary changes
include trilineage hyperplasia and polyclonal plasmacytosis.
Together, these findings can lead to misdiagnoses, including
benign lymphoid hyperplasia, T cell rich large B cell lymphoma,
chronic myeloproliferative disease, or plasma cell dyscrasia (15–
17). The consensus is that CD10, CXCL13, and PD-1 are
expressed in only a fraction of cases, although double labeling
with CD3 and BCL6 may specifically highlight the neoplastic T
cells (16). Additionally, depending on the methodology used, T-
cell receptor (TCR) gene rearrangements are seen in 70–90% of
cases and Ig gene rearrangements in approximately 10-20% of
cases (18).
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The association between polyclonal plasma cell proliferations
and AITL has not yet been fully elucidated. While it may in part
be secondary to cytokine release such as IL-6, in this case we
hypothesize that the EBV likely was a contributing factor (6).
EBV reactivation is known to occur when latently infected B cells
are exposed to a variety of stimuli, including physiologic signals
able to induce proliferation and differentiation (19). The specific
mechanisms leading to the occurrence of high levels of pEBVd in
AITL merit further investigation.
We report this clinical case study to emphasize the need for
consideration of AITL in patients presenting with peripheral
blood polyclonal plasmacytosis, high levels of pEBVd, and
features highly suggestive of lymphoma, such as extensive
lymphadenopathy and TLS. While the initial presentation and
tissue morphology appears consistent with a reactive process,
closer examination as above reveals histopathology consistent
with AITL. In previous reports of AITL with plasmacytosis,
patients who received rapid treatment showed a good response
to cytotoxic chemotherapy (20). The efficacy of treatment in
patients with AITL and significant EBV viral load remains less
well known.
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